A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Clinical trial NCT06161025 · RECRUITING
Trial details
- NCT number
- NCT06161025
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-27
- Primary completion
- 2028-02-29
- Enrollment
- 860
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.